Overview
- Filed in St. Louis Circuit Court, the proposal would create a nationwide program paying eligible non-Hodgkin lymphoma claimants over up to 21 years through capped, declining annual contributions.
- The agreement requires judicial approval and broad plaintiff participation, includes an opt-out option, allows Bayer to terminate if opt-outs are excessive, and contains no admission of wrongdoing.
- Bayer says the plan is designed to resolve most of the roughly 65,000–67,000 outstanding suits and compensate future diagnoses tied to pre‑Feb. 17, 2026 exposure, with tiered awards such as about $165,000 on average for certain younger occupational cases and $10,000 for the oldest claimants.
- The company raised litigation provisions to about €11.8 billion, secured an $8 billion loan facility, and warned 2026 free cash flow will turn negative as large payments come due.
- Investor reaction has been mixed, with shares jumping on the announcement before sliding up to 9% the next day, while Supreme Court arguments on federal preemption are scheduled for April 27.